Seizures as an early symptom of autosomal dominant Alzheimer's disease by Vöglein, Jonathan et al.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 1 
Seizures as an early symptom of autosomal dominant Alzheimer’s disease 1 
2 
Jonathan Vöglein, MD,1,2 Soheyl Noachtar, MD,2 Eric McDade, DO,3 Kimberly A. Quaid, 3 
PhD,4† Stephen Salloway, MD,5 Bernardino Ghetti, MD,6 James Noble, MD,7 Sarah Berman, 4 
MD, PhD,8 Jasmeer Chhatwal, MD, PhD,9 Hiroshi Mori, PhD,10 Nick Fox, MD,11 Ricardo 5 
Allegri, MD,12 Colin L. Masters, MD,13 Virginia Buckles, PhD,3 John M. Ringman, MD,14 6 
Martin Rossor, MD,11 Peter R. Schofield, PhD, DSc,15,16 Reisa Sperling, MD,9 Mathias 7 
Jucker, PhD,17,18 Christoph Laske, MD,17,19 Katrina Paumier, PhD,3 John C. Morris, MD,3 8 
Randall J. Bateman, MD,3 Johannes Levin, MD,1,2* Adrian Danek, MD1,2* for the 9 
Dominantly Inherited Alzheimer Network 10 
11 
1German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Straße 17, 81377 12 
Munich, Germany 13 
2Department of Neurology, University Hospital, LMU Munich, Marchioninistraße 15, 81377 14 
Munich, Germany 15 
3Washington University School of Medicine, 660 South Euclid, Saint Louis, MO 63110, 16 
USA 17 
4Department of Medical and Molecular Genetics, Indiana University, 975 West Walnut 18 
Street, Indianapolis, IN 46202, USA 19 
5Butler Hospital, 345 Blackstone Boulevard, Providence, RI 02906, USA 20 
6Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 21 
635 Barnhill Drive, MS A138, Indianapolis, IN 46202, USA 22 
7Columbia University, 710 W 168th St, New York, NY 10032, USA 23 
8University of Pittsburgh, 3471 Fifth Ave #900, Pittsburgh, PA 15213, USA 24 
9Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 55 25 
Fruit Street, Boston, MA 02114, USA  26 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Vöglein, J., Noachtar, S., McDade, E., Quaid, K. A., Salloway, S., Ghetti, B., … Danek, A. (2018). Seizures as an early symptom of 
autosomal dominant Alzheimer’s disease. Neurobiology of Aging. https://doi.org/10.1016/j.neurobiolaging.2018.11.022
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 2 
 
10Osaka City University Medical School, Asahi Machi, Abenoku, Osaka 545-8585, Japan 1 
11Dementia Research Centre, Institute of Neurology, University College London, Queen 2 
Square, London WC1 3BG, United Kingdom 3 
12FLENI, Montañeses 2325 (C1428AQK), Bs As, Argentina 4 
13Florey Institute, University of Melbourne, Level 5, Kenneth Myer Building, 30 Royal 5 
Parade, Parkville, Victoria 3010, Australia 6 
14Center for the Health Professionals, Keck School of Medicine of University of Southern 7 
California, 1540 Alcazar Street, Suite 209F, Los Angeles, CA 90089, USA 8 
15Neuroscience Research Australia, Barker Street, Randwick NSW 2031, Australia 9 
16School of Medical Sciences, University of New South Wales, Sydney NSW 2052, Australia 10 
17German Center for Neurodegenerative Diseases (DZNE), Otfried-Müller-Straße 23, 72076 11 
Tübingen, Germany 12 
18Hertie Institute of Clinical Brain Research, University of Tübingen, Otfried-Müller-Straße 13 
27, 72076 Tübingen, Germany 14 
19Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department 15 
of Psychiatry and Psychotherapy, University of Tübingen, Osianderstraße 24, 72076 16 
Tübingen, Germany 17 
 18 
 19 
*Corresponding authors: 20 
Johannes Levin, MD; Adrian Danek, MD 21 
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany 22 
Department of Neurology, University Hospital, LMU Munich, Germany 23 
Marchioninistraße 15 24 
81377 Munich, Germany 25 
Phone 0049 89 4400 46458 26 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 3 
 
Fax 0049 89 4400 46560 1 
johannes.levin@med.uni-muenchen.de; adrian.danek@med.uni-muenchen.de 2 
 3 
†Deceased 26 July 2017. 4 
 5 
 6 
Word count paper: 2932 7 
Word count abstract: 149 8 
Number of references: 26 9 
Number of figures: 2  10 
Number of tables: 2 11 
  12 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 4 
 
Authors: 1 
Jonathan Vöglein; jonathan.voeglein@med.uni-muenchen.de 2 
Soheyl Noachtar; soheyl.noachtar@med.uni-muenchen.de 3 
Eric McDade; ericmcdade@wustl.edu 4 
Kimberly A. Quaid; kquaid@iupui.edu 5 
Stephen Salloway; ssalloway@butler.org 6 
Bernardino Ghetti; bghetti@iupui.edu 7 
James Noble; jn2054@columbia.edu 8 
Sarah Berman; bermans@upmc.edu 9 
Jasmeer Chhatwal; Chhatwal.Jasmeer@mgh.harvard.edu 10 
Hiroshi Mori; mori@med.osaka-cu.ac.jp 11 
Nick Fox; n.fox@ucl.ac.uk 12 
Ricardo Allegri; rallegri@fleni.org.ar 13 
Colin L. Masters; c.masters@florey.edu.au 14 
Virginia Buckles; bucklesv@abraxas.wustl.edu 15 
John M. Ringman; ringman@usc.edu 16 
Martin Rossor; m.rossor@ucl.ac.uk 17 
Peter R. Schofield; p.schofield@neura.edu.au 18 
Reisa Sperling; reisa@rics.bwh.harvard.edu 19 
Mathias Jucker; mathias.jucker@uni-tuebingen.de 20 
Christoph Laske; christoph.laske@med.uni-tuebingen.de 21 
Katrina Paumier; kpaumier@yahoo.com 22 
John C. Morris; morrisj@abraxas.wustl.edu 23 
Randall J. Bateman; batemanr@wustl.edu 24 
Johannes Levin; johannes.levin@med.uni-muenchen.de 25 
Adrian Danek; adrian.danek@med.uni-muenchen.de  26 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 5 
 
Author Contributions: 1 
Jonathan Vöglein: writing the manuscript, study concept and design, acquisition of data, 2 
analysis and interpretation of data 3 
Soheyl Noachtar: analysis and interpretation of data, critical revision of manuscript for 4 
intellectual content 5 
Eric McDade: critical revision of manuscript for intellectual content 6 
Kimberly A. Quaid: critical revision of manuscript for intellectual content 7 
Stephen Salloway: critical revision of manuscript for intellectual content 8 
Bernardino Ghetti: critical revision of manuscript for intellectual content 9 
James Noble: critical revision of manuscript for intellectual content 10 
Sarah Berman: critical revision of manuscript for intellectual content 11 
Jasmeer Chhatwal: critical revision of manuscript for intellectual content 12 
Hiroshi Mori: critical revision of manuscript for intellectual content 13 
Nick Fox: critical revision of manuscript for intellectual content 14 
Ricardo Allegri: critical revision of manuscript for intellectual content 15 
Colin L. Masters: critical revision of manuscript for intellectual content 16 
Virginia Buckles: critical revision of manuscript for intellectual content 17 
John M. Ringman: critical revision of manuscript for intellectual content 18 
Martin Rossor: critical revision of manuscript for intellectual content 19 
Peter R. Schofield: critical revision of manuscript for intellectual content 20 
Reisa Sperling: critical revision of manuscript for intellectual content 21 
Mathias Jucker: critical revision of manuscript for intellectual content 22 
Christoph Laske: critical revision of manuscript for intellectual content 23 
Katrina Paumier: critical revision of manuscript for intellectual content 24 
John C. Morris: critical revision of manuscript for intellectual content 25 
Randall J. Bateman: critical revision of manuscript for intellectual content 26 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 6 
 
Johannes Levin: study concept and design, analysis and interpretation of data, critical 1 
revision of manuscript for intellectual content, study supervision 2 
Adrian Danek: study concept and design, analysis and interpretation of data, critical revision 3 
of manuscript for intellectual content, study supervision 4 
 5 
 6 
Disclosure statement: 7 
Jonathan Vöglein reports no disclosures 8 
Soheyl Noachtar reports no disclosures 9 
Eric McDade reports no disclosures 10 
Kimberly A. Quaid is deceased; disclosures are not included for this author  11 
Stephen Salloway reports no disclosures 12 
Bernardino Ghetti reports no disclosures 13 
James Noble reports no disclosures 14 
Sarah Berman reports no disclosures 15 
Jasmeer Chhatwal reports no disclosures 16 
Hiroshi Mori reports no disclosures 17 
Nick Fox reports no disclosures 18 
Ricardo Allegri reports no disclosures 19 
Colin L. Masters reports no disclosures 20 
Virginia Buckles reports no disclosures 21 
John M. Ringman reports no disclosures 22 
Martin Rossor reports no disclosures 23 
Peter R. Schofield reports no disclosures 24 
Reisa Sperling reports no disclosures 25 
Mathias Jucker reports no disclosures 26 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 7 
 
Christoph Laske reports no disclosures 1 
Katrina Paumier reports no disclosures 2 
John C. Morris reports no disclosures 3 
Randall J. Bateman reports no disclosures 4 
Johannes Levin reports no disclosures 5 
Adrian Danek reports no disclosures 6 
 7 
 8 
Acknowledgements: 9 
This project was supported by The Dominantly Inherited Alzheimer’s Network (DIAN, UF1 10 
AG032438) funded by the National Institute on Aging (NIA), the German Center for 11 
Neurodegenerative Diseases (DZNE), the NIHR Queen Square Dementia Biomedical 12 
Research Centre and the MRC Dementias Platform UK (MR/L023784/1 and MR/009076/1). 13 
This manuscript has been reviewed by DIAN Study investigators for scientific content and 14 
consistency of data interpretation with previous DIAN Study publications. We acknowledge 15 
the altruism of the participants and their families and contributions of the DIAN research and 16 
support staff at each of the participating sites for their contributions to this study. The authors 17 
thank Ingrid Ricard (Institute for Medical Informatics, Biometry & Epidemiology, Ludwig-18 
Maximilians-Universität München, Munich, Germany) for statistical consulting. 19 
 20 
 21 
 22 
  23 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 8 
 
Abstract  1 
 2 
Our objective was to assess the reported history  of seizures in cognitively asymptomatic 3 
mutation carriers for autosomal dominant Alzheimer’s disease (ADAD) and the predictive 4 
value of seizures for mutation carrier status in cognitively asymptomatic first – degree 5 
relatives of ADAD patients. Seizure occurrence in the Dominantly Inherited Alzheimer 6 
Network (DIAN) observational study was correlated with mutation carrier status in 7 
cognitively asymptomatic subjects. Of 276 cognitively asymptomatic individuals, 11 (4%) 8 
had experienced seizures, and nine out of these carried an ADAD mutation. Thus, in the 9 
DIAN population seizure frequency in mutation carriers was significantly higher than in non 10 
– carriers (P = .04) and the positive predictive value of seizures for the presence of a 11 
pathogenic mutation was 81.8%. Among cognitively asymptomatic ADAD family members, 12 
the occurrence of seizures increases the a priori risk of 50% mutation positive status to about 13 
80%. This finding suggests that ADAD mutations increase the risk of seizures. 14 
 15 
 16 
Keywords: Alzheimer’s disease; Autosomal dominant; Seizures; Positive Predictive Value; 17 
Dementia; Genetics 18 
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1. Introduction 1 
 2 
Autosomal dominant Alzheimer’s disease (ADAD) is a rare form of Alzheimer’s disease 3 
(less than one percent of all AD cases)(Bird TD. Alzheimer Disease Overview. 1998 Oct 23 4 
[Updated 2015 Sep 24]. In: Pagon RA) that usually has an earlier symptomatic onset (35 to 5 
55 years) relative to sporadic AD (Ryman et al., 2014). First-degree relatives of persons with 6 
ADAD are at 50% risk for carrying a disease-causing mutation in one of the three known 7 
ADAD genes: PSEN1, PSEN2, and APP, coding for presenilin 1, presenilin 2 and amyloid 8 
precursor protein, respectively. Such mutations cause ADAD with almost complete 9 
penetrance (Jayadev et al., 2010). The Dominantly Inherited Alzheimer Network (DIAN) 10 
observational study aims to reveal the pathological changes in the course of ADAD, 11 
particularly in the period before cognitive decline (Bateman et al., 2012). 12 
Interictal epileptiform discharges measured by electroencephalography and overt seizures 13 
have been reported in transgenic mouse models of AD (Born, 2015; Palop and Mucke, 2010). 14 
Persons with AD are at an increased risk for seizures (Horvath et al., 2016; Nicastro et al., 15 
2016), in particular those with an early age of onset (Amatniek et al., 2006) and in advanced 16 
stages (Romanelli et al., 1990). Pathogenic ADAD mutations or APP duplications may confer 17 
an even higher risk of seizures than in sporadic AD (Born, 2015). In accordance with the 18 
2012 classification scheme of the International League Against Epilepsy (Panayiotopoulos, 19 
2012), ADAD due to PSEN1 mutations was even proposed as a genetic epilepsy syndrome 20 
(Larner, 2011). Recently, the DIAN observational study has reported seizures in 2.8% of 21 
symptomatic ADAD mutations carriers (Tang et al., 2016). Based on evidence that AD starts 22 
much earlier than its cognitive manifestation (Bateman et al., 2012), we hypothesized that 23 
asymptomatic (i.e. Clinical Dementia Rating (CDR) (Morris, 1993) score of 0) ADAD 24 
mutation carriers show a higher frequency of seizures than non-carriers. 25 
  26 
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2. Methods 1 
 2 
2.1. Study population 3 
Data from the DIAN observational study, collected using the Uniform Data Set of the 4 
National Alzheimer’s Coordinating Center (NACC-UDS2) (Morris et al., 2006) with 5 
examiners blinded to and participants mostly unaware of mutation status at 15 sites in the 6 
USA, Australia, the UK and Germany from January 2009 to January 2015 (data freeze 9), 7 
formed the basis for our analysis. The data set included extensive information about 144 8 
participants with PSEN1, PSEN2, and APP mutations and non-mutation carrying ADAD 9 
family members (n = 132) who served as controls. The protocol for the study received 10 
approval by the institutional review boards at all participating sites. The study was performed 11 
in accordance with the declaration of Helsinki. Written informed consent was obtained from 12 
each subject. 13 
 14 
2.2. Seizure assessment 15 
Seizure occurrence is assessed by a single item in the NACC-UDS (question 4a on form A5). 16 
We analyzed the occurrence of seizures by evaluating this item along with the adverse event 17 
forms for all visits included in data freeze nine in all cognitively asymptomatic participants 18 
(defined by a CDR score of 0). NACC-UDS asks for characterization of seizures in four 19 
mutually exclusive categories: “recent/active” (happened within the last year or still requiring 20 
active management), “remote/inactive” (existing or occurring in the past, i.e. more than one 21 
year ago, having been resolved or without current treatment), “absent” and “unknown”, 22 
respectively. Evaluation is based on report of the subject and the accompanying informant, 23 
medical records and/or observation (Figure 1).  24 
 25 
2.3. Other variables 26 
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Additional DIAN study data that were included in our analysis of cognitively asymptomatic 1 
participants are age and gender, apolipoprotein E (APOE) genotype (allele combinations 2 
ɛ2/ɛ2, ɛ2/ɛ3, ɛ2/ɛ4, ɛ3/ɛ3, ɛ3/ɛ4 or ɛ4/ɛ4, respectively) and, if applicable, gene affected and 3 
expected age of onset (EAO). EAO is defined as the age of ADAD symptom onset in the 4 
index patient in the family of a DIAN participant and has been shown to be a predictor of the 5 
age of onset of ADAD symptoms in the respective family (Bateman et al., 2012; Ryman et 6 
al., 2014). Time to EAO is the difference in years (whole numbers) between EAO and the 7 
current age of the participant at the time of the visit. 8 
 9 
2.4. Comorbidities 10 
The data set was also screened for additional factors that might cause or mimic seizures such 11 
as alcohol and substance abuse, syncope, diabetes and other medical comorbidities, as well as 12 
for a history of stroke and other neurologic and psychiatric comorbidities such as traumatic 13 
brain injury (TBI). Three degrees of TBI are distinguished in NACC-UDS: 1. TBI with brief 14 
loss of consciousness of less than 5 minutes, 2. TBI with extended loss of consciousness 15 
(greater than or equal to 5 minutes), and 3. TBI with chronic deficit or dysfunction, with each 16 
classified as either “absent” or “recent/active” or “remote/inactive” or “unknown”. We 17 
identified three individuals with TBI in the study population and assessed their FLAIR MR 18 
images with specific emphasis on epileptogenic brain lesions. These MR images were 19 
performed during the DIAN study visit at which a history of TBI was recorded and all of the 20 
TBI were stated “remote/inactive”.  There was therefore at least a one year interval between 21 
the TBI and the MRI.  We compared the prevalence of TBI in subjects with seizures between 22 
mutation carriers and non-carriers using Fisher’s exact test.  23 
 24 
2.5. Data and statistical analysis 25 
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For comparison of subjects’ baseline age, EAO and time to EAO between mutation carriers 1 
and non-carriers Student´s t-test was used. Gender, affected gene (PSEN1, PSEN2, or APP) 2 
and APOE genotype were compared using Fisher’s exact test.  3 
Due to the small number of individuals with seizures, a right-sided one-tailed Fisher’s exact 4 
test was performed to test the hypothesis of a higher frequency of seizures in mutation 5 
carriers compared to non-carriers.  6 
Sensitivity, specificity, and the positive predictive value of seizure occurrence with respect to 7 
mutation carrier status were calculated using a two-dimensional contingency table. 8 
To analyze the timing of seizures in the cognitively asymptomatic stage of ADAD mutation 9 
carriers we assumed that the seizure had occurred at the latest possible time point for each 10 
individual participant: we posited that if seizures were stated as “recent/active” they 11 
happened on the day of the study visit. If seizures were stated as “remote/inactive” (occurred 12 
more than a year ago) it was assumed that they had happened exactly one year before the 13 
study visit. We used the first study visit at which presence of seizures was mentioned (i.e. as 14 
“recent/active” or “remote/inactive”, in contrast to “absent” or “unknown”) for subsequent 15 
calculations. For group comparisons we put the latest possible time point of seizure 16 
occurrence in relation to EAO. Because of repeated claims of an increased seizure risk 17 
particularly of PSEN1 mutations, the latest possible time point of seizure occurrence in 18 
relation to EAO was studied in individuals with PSEN1 mutations in comparison to those 19 
with PSEN2 or APP mutations, utilizing a two-sided t-test. 20 
To compare seizure frequency of asymptomatic carriers of ADAD mutations (i.e. CDR = 0) 21 
with that in carriers already affected by cognitive symptoms of ADAD (CDR of 0.5 and 22 
above), we drew on data obtained in another analysis of the DIAN data set (Tang et al., 2016) 23 
and used two-sided Fisher’s exact test for the comparison of the cognitively asymptomatic 24 
and symptomatic states. 25 
  26 
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3. Results 1 
 2 
3.1. Population characteristics 3 
The DIAN data set under analysis contained data from 276 cognitively asymptomatic 4 
participants (CDR = 0), 144 of which were carriers of mutations in PSEN1, PSEN2, or APP 5 
and 132 were non-mutation carrying ADAD family members. Mutation carriers were 6 
significantly younger than non-carriers and had a longer time to the expected age of onset 7 
(EAO) of their family mutations. Otherwise, no significant baseline differences between the 8 
two groups were found (Table 1). 9 
 10 
3.2. Reported history of seizures  11 
Among these 276 individuals, seizures were reported in 11 participants (4%) and of these, 9 12 
participants (81.8%) were ADAD mutation carriers (Figure 2). Fisher’s exact test showed a 13 
significantly higher frequency of seizures in mutation carriers compared to non-carriers 14 
(6.3% vs. 1.5%, p = 0.04).  15 
 16 
3.3. Predictive value 17 
Occurrence of seizures corresponds to a sensitivity of 6.3%, a specificity of 98.5% and a 18 
positive predictive value of 81.8% for the presence of an ADAD mutation within the 19 
population of cognitively unaffected ADAD mutation carriers and non-carriers in the DIAN 20 
observational study. 21 
 22 
3.4. Seizures and mutation types 23 
No significant correlation between seizure occurrence and mutation types (number of 24 
mutation carriers with seizures: PSEN1 = 5, PSEN2 = 2, APP = 2) was found (Table 1). The 25 
well-known preponderance of PSEN1 mutations in ADAD is reflected in our study 26 
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population, with a ratio of 100 to 35 of PSEN1 versus PSEN2 and APP mutations in the 1 
mutation carriers without seizures. However, it appears shifted in favor of PSEN2 and APP 2 
mutations to a ratio of 5 to 4, if seizures occur. Although this suggests that seizures may be 3 
more common in association with PSEN2 and APP mutations, the difference was not 4 
significant (p = 0.25). It is possible that a larger sample size would verify this association, 5 
since a theoretical calculation in an assumed sample with unaltered gene mutation 6 
distributions but threefold size would result in a more suggestive p value of 0.04. 7 
 8 
3.5. Seizures in the time course of ADAD 9 
Among the 9 ADAD mutation carriers with seizures, they were stated as “remote/inactive” in 10 
8 and as “recent/active” in one. On average, the latest possible time point of seizure 11 
occurrence determined with the method described above was 14 years prior to EAO (standard 12 
deviation 10.4 years). Although not significant (p = 0.06), seizures in PSEN1 mutations 13 
appeared earlier than in PSEN2 and APP mutations (mean -19.6 and -7 years to EAO, 14 
respectively) with respect to EAO. 15 
 16 
3.6. Comorbidities 17 
In 3 individuals with seizures, one episode each of TBI was reported in their histories, all 18 
with brief loss of consciousness of less than 5 minutes, and all stated “remote/inactive”. 19 
Further, the TBI occurred not necessarily before the appearance of seizures. FLAIR MR 20 
images in these three cases did not reveal any apparent epileptogenic brain lesions related to 21 
TBI, such as temporobasal or other cortical contusions. In subjects with seizures, no 22 
statistically significant difference in frequency of TBI between mutation carriers and non-23 
carriers was found (p = 1.0). No other possibly contributing factors were evident in 24 
individuals affected by seizures (Table 2). In the 2 non-carriers with seizures, no specific 25 
reasons could be identified from the dataset.  26 
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4. Discussion 1 
 2 
Our data suggest an increased lifetime prevalence of seizures in cognitively unaffected 3 
carriers of mutations in three genes underlying autosomal dominant Alzheimer‘s disease 4 
(PSEN1, PSEN2, APP). French authors initially had suggested that seizures that occurred 5 
several years before cognitive onset in their ADAD family SAL510 might be related to the 6 
L235P PSEN1 mutation, yet two children of a mutation-unaffected family member had 7 
seizures similar to the childhood-onset epilepsy of their L235P-carrying grandfather and 8 
parental sibling, respectively (Campion et al., 1996). The cohort of the French PHRC GMAJ 9 
(Programme Hospitalier de Recherche Clinique-Génétique Malades Alzheimer Jeunes) 10 
collaborators was reported to include four subjects with seizures as the very first symptom 11 
among 132 mutation carriers from 77 ADAD families (i.e. in 3% of the PHRC GMAJ 12 
subjects) and, according to the supplemental data provided, the SAL510 family members 13 
were not part of that recent analysis (Zarea et al., 2016). Our analysis of the DIAN data set 14 
with its non-mutation carrying family members as controls strengthens the French findings: 15 
we found a statistically significant group difference in the lifetime prevalence of a reported 16 
seizure between ADAD mutation carriers and non-carriers. In the entire DIAN cohort with its 17 
251 mutation carriers, emerging from 144 cognitively asymptomatic mutation carriers of our 18 
analysis and 107 symptomatic mutation carriers of the work of Tang et al., 9 individuals 19 
suffered from seizures as the initial ADAD symptom. This leads to a proportion of 3.6% of 20 
mutation carriers with seizures as the first symptom of ADAD matching the French result of 21 
3%. For comparison, estimates in epidemiological studies with respect to prevalence of 22 
epilepsy are reaching from 0.4% to 1% in different populations (Sander, 2003). 23 
Another detailed evaluation of ADAD patients caused by mutations in PSEN1 (n = 85) and 24 
APP (n = 36) described seizures in 20 PSEN1 and in 9 APP mutation carriers. Hence, 25 
throughout their entire lives around 25% of mutation carriers with either gene had a seizure 26 
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(Ryan et al., 2016). Notably, in 9 of the 29 patients with seizures, the seizures had occurred at 1 
least 5 years before symptom onset. These figures can be recalculated into a seizure incidence 2 
of 7.4% (9/121) in cognitively asymptomatic mutation carriers which is close to the 6.3% 3 
obtained in the present analysis. 4 
The recent evaluation of 107 DIAN subjects already symptomatic with ADAD only analyzed 5 
“recent/active” seizures according to NACC-UDS (Tang et al., 2016). The reported 6 
proportion of 2.8% (three individuals) is lower than the 6.3% of cognitively unaffected 7 
mutation carriers from our analysis, which also considered seizures that had occurred more 8 
than a year prior to the study visit (“remote/inactive”). In any case, there is no statistically 9 
significant difference with respect to seizure frequency in the cognitively symptomatic and 10 
asymptomatic groups (p = 0.2).  11 
In the majority (89%) of asymptomatic mutation carriers studied, seizures occurred at least 12 
one year before the respective study visit, and were classified as resolved or untreated. These 13 
data might indicate that seizures in asymptomatic ADAD are of a benign nature. The early 14 
appearance in relation to EAO and the apparent lack of difference in seizure frequency 15 
between asymptomatic and symptomatic ADAD mutation carriers supports the assumption 16 
that the pathomechanism underlying the seizures, although present early, remains stable from 17 
the asymptomatic stage through to the manifestation of ADAD. This might be taken as an 18 
argument against instituting antiepileptic pharmacotherapy after a first seizure in cognitively 19 
asymptomatic subjects at risk for ADAD beyond consideration of current guidelines (Fisher 20 
et al., 2014) and sociocultural consequences (i.e. regarding employment, driving license) of a 21 
seizure relapse for treatment decisions. 22 
Despite repeated reports of a particular association of PSEN1 mutations with epilepsy, 23 
culminating in the bold proposal to acknowledge PSEN1-related ADAD as a genetic epilepsy 24 
syndrome (Larner, 2011), our data do not support a specific association of seizures with 25 
PSEN1 mutations. In fact, we found PSEN1 mutation carriers might be less commonly 26 
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affected by seizures than PSEN2 and APP mutation carriers. Firm conclusions as to the 1 
specific influence of distinct mutations would be premature, due to the lack of sufficient data. 2 
As an example, none of the 19 symptomatic APP mutation carriers reported in Tang et al. 3 
(Tang et al., 2016) had seizures, whereas in our sample 2 out of the 24 asymptomatic APP 4 
mutation carriers were affected. Taking into account the study of Ryan et al. (Ryan et al., 5 
2016) that found 9 out of 36 carriers affected, seizures are a feature in about 14% of APP 6 
mutation carriers. 7 
With a positive predictive value of 81.8% for the presence of an ADAD mutation, the 8 
occurrence of seizures signals a shift from the a priori value of 50% genetic risk for members 9 
of affected families. Despite an increased risk on the order of 80% for having a pathogenic 10 
mutation, it is important to note that the risk is not absolute. That is, 2 of the 11 asymptomatic 11 
individuals experiencing seizures did not carry a pathogenic mutation, which indicates the 12 
occurrence of seizure in cognitively normal members of these families should not be 13 
considered as evidence of mutation status.  Moreover, our findings represent an association of 14 
seizures with mutation status, but we do not have the data to consider causality.  It is possible 15 
that non-genetic factors were responsible for the seizure history in at least some of the 9 16 
mutation carriers. In all cases, appropriate clinical evaluation after seizure occurrence is 17 
strongly recommended. 18 
A clear limitation of our analysis lies in the method used to ascertain seizure history. EEG 19 
examinations, that would be helpful to corroborate an epileptic cause of an event reported as 20 
seizure, are not part of the DIAN observational study protocol. EEG might further yield the 21 
opportunity to detect subclinical seizures, known to occur in AD (Lam et al., 2017). 22 
Potentially provoking factors or types of seizures are not assessed in a standardized manner 23 
with the NACC-UDS2. As this tool of the DIAN study does not define the term “seizure” in 24 
detail, it can only be considered a rough surrogate for actual epileptic events. Further, 25 
knowledge about carrying a mutation or not might have influenced a participant´s willingness 26 
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to report symptoms from his or her history. Owed to the small number of participants with 1 
seizures in this study, these results must be further validated. Optimized assessment in 2 
ADAD cohorts such as followed in the DIAN studies could include long-term overnight EEG 3 
in addition to standardized, routine seizure work-up.  4 
A recent study reported subclinical epileptiform activity, as ascertained with overnight long-5 
term video-electroencephalography, in more than 40% of patients with sporadic AD (Vossel 6 
et al., 2016). Given this percentage, analyzing the value of seizure occurrence in a cognitively 7 
healthy population to predict the occurrence of cognitively symptomatic sporadic 8 
Alzheimer’s disease and a comparison to the 82 % positive predictive value in ADAD 9 
described here could be worthwhile. 10 
These clinical findings do suggest a relationship between presymptomatic seizures and the 11 
effects of ADAD mutations, which deserves further study. A potential explanation for this 12 
relationship could be a lowering of the seizure threshold through ADAD mutations that may 13 
account for the relatively rare and non-recurring seizures in the asymptomatic stage of the 14 
disease. An association of ADAD causing mutations and seizures is experimentally supported 15 
by data from various transgenic mouse models that display early amyloid β-associated 16 
neuronal hyperactivity and epileptiform activity (Busche and Konnerth, 2016; Palop and 17 
Mucke, 2010). Further, a connection was shown in the Colombian E280A PSEN1 family: 5 18 
affected persons who had epileptic seizures and came to autopsy showed neuronal loss in the 19 
CA1 field of the hippocampus similar to the typical finding in epilepsy patients with 20 
hippocampal sclerosis (Velez-Pardo et al., 2004). Another possible link is provided through 21 
the case of a PSEN1 S169L mutation carrier who suffered from seizures and showed ectopic 22 
white matter neurons in the post-mortem neuropathological examination (Takao et al., 2001). 23 
The occurrence of seizures might help to identify cognitively as yet unaffected mutation 24 
carriers in ADAD families, which is of particular interest with respect to possible inclusion of 25 
such individuals in the asymptomatic treatment studies that are currently under way such as 26 
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the DIAN Trials Unit (NCT01760005) or the Alzheimer Prevention Initiative 1 
(NCT01998841) (Rohrer, 2015. http://www.neurodegenerationresearch.eu/wp-2 
content/uploads/2015/10/JPND-Report-Rohrer.pdf). Hereby these persons with a 3 
significantly increased mutation positive risk could be provided the opportunity to receive a 4 
potentially effective treatment. Further, new ADAD pedigrees could be identified based on a 5 
family history of early onset dementia and seizures. 6 
Antiepileptic treatment decisions after seizures in individuals at risk for ADAD may consider 7 
the low risk of ongoing seizures in cognitively asymptomatic mutation carriers.  This 8 
suggests that genetic testing may not be warranted solely for seizure management of ADAD 9 
family members. However, the increased risk of being a mutation carrier may prompt interest 10 
in appropriate genetic counseling and testing. 11 
Finally, carrier status of a mutation in one of the three ADAD genes, PSEN1, PSEN2, or 12 
APP, even if rare, appears to be a reasonable differential diagnosis in the work-up of seizures 13 
in adults, particularly with a family history suggesting early onset dementia. 14 
 15 
  16 
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Figures 1 
 2 
 3 
 4 
Figure 1: Excerpt from the coding guidebook version 2 for the Uniform Data Set version 2 of 5 
the National Alzheimer’s Coordinating Center (NACC-UDS2) that has been used for 6 
assessment of seizures. (A) General instructions and criteria for assessment of the 7 
participant’s health history. (B) Single Item question for the assessment of seizures. 8 
 9 
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 1 
 2 
Figure 2: Relation of mutation status and seizures. (A) Proportion of mutation carriers in 3 
subjects with and without seizures. (B) Number of subjects with seizures among mutation 4 
carriers and non-carriers. 5 
 6 
 7 
 8 
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Tables 1 
 2 
 3 
Table 1: Title: Study population characteristics. Legend: For group comparisons concerning 4 
age, EAO and time to EAO t-tests and for the other items Fisher’s exact tests were 5 
performed. No statistically significant difference in distribution of APOE genotypes between 6 
mutation carriers and non-carriers were found. Abbreviations: EAO, expected age of onset of 7 
family mutations. 8 
 9 
 10 
  11 
Variable 
Mutation carriers       
(n = 144) 
Non-carriers         
(n = 132) Total (n = 276) p Value 
Mean age ± SD, y 35 ± 9.2 38.3 ± 10.2 36.5 ± 9.8 0.01 
Female : male, n 61 : 83 58 : 74 119 : 157 0.81 
Mean EAO ± SD, y 47.5 ± 7.1 46.9 ± 6.7 47.2 ± 6.9 0.47 
Mean time to EAO ± SD, y 12.5 ± 7.9 8.6 ± 11.5 10.6 ± 10.0 0.001 
Seizures, n (%) 9 (6.3) 2 (1.5) 11 (4) 0.04 
Family mutation type, PSEN1 : PSEN2 : APP, n 
Seizures, n (%) of mutation type 
No seizures, n of mutation type 
105 : 15 : 24 
5 (4.8) : 2 (13.3) : 2 (8.3) 
100 : 13 : 22 
84 : 12 : 36 
2 : 0 : 0 
82 : 12 : 36 
189 : 27 : 60 
7 : 2 : 2 
182 : 25 : 58 
0.1 
1.0 
0.08 
APOE genotype, ɛ2/ɛ2 : ɛ2/ɛ3 : ɛ2/ɛ4 : ɛ3/ɛ3 : ɛ3/ɛ4 : ɛ4/ɛ4, n 1 : 10 : 6 : 96 : 29 : 2 1 : 15 : 2 : 78 : 34 : 2 2 : 25 : 8 : 174 : 63 : 4 0.41 
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Comorbidity 
Subjects with seizures    
(n = 11) 
Subjects without seizures 
(n = 265) Total (n = 276) 
Alcohol abuse, n 0 14 14 
Substance abuse, n 0 16 16 
Stroke, n 1* 1 2 
Diabetes, n 0 3 3 
Traumatic brain injury, n 3 47 50 
 1 
Table 2: Title: Relevant comorbidities in the histories of the 276 cognitively asymptomatic 2 
DIAN study participants analyzed, separated into groups with and without seizures, 3 
respectively. Legend: The 3 individuals with seizures and traumatic brain injury (loss of 4 
consciousness less than 5 minutes in all cases) in their histories showed no related lesions on 5 
brain MRI FLAIR images. *Stroke occurred after seizures had developed. 6 
 7 
 8 
 9 
 10 
 11 
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Seizures as an early symptom of autosomal dominant Alzheimer’s disease 
 
Highlights 
 
• Seizure prevalence is increased in cognitively asymptomatic ADAD mutation carriers.  
• Epileptic seizures have a predictive value for mutation carrier status in ADAD.  
• Seizures may manifest early in the cognitive healthy state of ADAD.  
 
 
